Monoklonale Antikörper verbessern Behandlung der schubförmigen Multiplen Sklerose

R. Gold; H.-P. Hartung; R. Hohlfeld

doi:10.1055/s-2006-924918

DMW - Deutsche Medizinische Wochenschrift, Table of Contents

Dtsch Med Wochenschr 2006; 131(1/2): 31-34
DOI: 10.1055/s-2006-924918

Arzneimittel & Pharmakotherapie

Monoklonale Antikörper verbessern Behandlung der schubförmigen Multiplen Sklerose

Molekulare Grundlagen und klinische Ergebnisse der anti-VLA4- (Natalizumab)-TherapieMonoclonal antibodies improve therapy of relapsing multiple sclerosisMolecular mechanisms and clinical results of anti-VLA4 therapy (natalizumab)R. Gold¹ , H.-P Hartung² , R. Hohlfeld³

¹Institut für MS-Forschung, Bereich Humanmedizin der Universität Göttingen und Gemeinnützige Hertie-Stiftung
²Neurologische Klinik der Heinrich Heine Universität, Düsseldorf
³Institut für Klinische Neuroimmunologie, Ludwig-Maximilians-Universität, München

Abstract

Full Text

References

Literatur

1 Archelos J J, Hartung H -P. The role of adhesion molecules in multiple sclerosis: biology, pathogenesis and therapeutic implications. Mol Med Today. 1997; 3 310-321
2 Baron J L, Madri J A, Ruddle N H, Hashim G, Janeway C A. Surface expression of alpha4 integrin by CD4 T cells is required for their entry into brain parenchyma. J Exp Med. 1993; 177 57-68
3 Berger J R, Koralnik I J. Progressive Multifocal Leukoencephalopathy and Natalizumab - Unforeseen Consequences. N Engl J Med. 2005; 353 414-416
4 Butcher E C, Williams M, Youngman K, Rott L, Briskin M. Lymphocyte trafficking and regional immunity. Adv Immunol. 1999; 72 209-253
5 Enders U, Lobb R, Pepinsky R B, Hartung H -P, Toyka K V, Gold R. The role of the very late antigen-4 (VLA-4) and its counterligand vascular cell adhesion molecule-1 (VCAM-1) in the pathogenesis of experimental autoimmune neuritis (EAN) of the Lewis rat. Brain. 1998; 121 1257-1266
6 Ghalie R G, Edan G, Laurent M. et al . Cardiac adverse effects associated with mitoxantrone (novantrone) therapy in patients with MS. Neurology. 2002; 59 909-913
7 Ghalie R G, Mauch E, Edan G. et al . A study of therapy-related acute leukaemia after mitoxantrone therapy for multiple sclerosis. Mult Scler. 2002; 8 441-445
8 Gold R, Hartung H -P, Toyka K V. Animal models for autoimmune demyelinating disorders of the nervous system. Mol Med Today. 2000; 6 88-91
9 Kieseier B C, Hartung H P. Current disease-modifying therapies in multiple sclerosis. Sem Neurol. 2003; 23 133-145
10 Leone D R, Giza K, Gill A. et al . An assessment of the mechanistic differences between two integrin alpha(4)beta(1) inhibitors, the monoclonal antibody TA-2 and the small molecule BIO5192, in rat experimental autoimmune encephalomyelitis. J Pharmacol Exp Ther. 2003; 305 1150-1162
11 Miller D H, Khan O A, Sheremata W A. et al . A controlled trial of natalizumab for relapsing multiple sclerosis. N Engl J Med. 2003; 348 15-23
12 MS-Therapie Konsensusgruppe (MSTKG) . Immunmodulatorische Stufentherapie der Multiplen Sklerose. Nervenarzt. 1999; 70 371-386
13 Muller W A. Leukocyte-endothelial-cell interactions in leukocyte transmigration and the inflammatory response. Trends Immunol. 2003; 24 327-334
14 Noseworthy J H, Gold R, Hartung H P. Treatment of multiple sclerosis: recent trials and future perspectives. Curr Opin Neurol. 1999; 12 279-293
15 Ransohoff R M. Natalizumab and PML. Nat Neurosci. 2005; 8 1275
16 Selmaj K, Walczak A, Mycko M, Berkowicz T, Kohno T, Raine C S. Suppression of experimental autoimmune encephalomyelitis with a TNF binding protein (TNFbp) correlates with down-regulation of VCAM-1/VLA-4. Eur J Immunol. 1998; 28 2035-2044
17 Soilu-Hänninen M, Röyttä M, Salmi A, Salonen R. Therapy with antibody against leukocyte integrin VLA-4 (CD49d) is effective and safe in virus-facilitated experimental allergic encephalomyelitis. J Neuroimmunol. 1997; 72 95-105
18 Steeber D A, Venturi G M, Tedder T F. A new twist to the leukocyte adhesion cascade: intimate cooperation is key. Trends Immunol. 2005; 26 9-12
19 Theien B E, Vanderlugt C L, Eagar T N. et al . Discordant effects of anti-VLA-4 treatment before and after onset of relapsing experimental autoimmune encephalomyelitis. J Clin Invest. 2001; 107 995-1006
20 Tubridy N, Behan P O, Capildeo R. et al . The effect of anti-alpha4 integrin antibody on brain lesion activity in MS. The UK Antegren Study Group (see comments). Neurology. 1999; 53 466-472
21 Vajkoczy P, Laschinger M, Engelhardt B. alpha 4-integrin-VCAM-1 binding mediates G protein - independent capture of encephalitogenic T cell blasts to CNS white matter microvessels. J Clin Invest. 2001; 108 557-565
22 Wiendl H, Kieseier B C. Disease-modifying therapies in multiple sclerosis: an update on recent and ongoing trials and future strategies. Exp Opin Invest Drugs. 2003; 12 689-712
23 Yednock T A, Cannon C, Fritz L C, Sanchez-Madrid F, Steinman L, Karin N. Prevention of experimental autoimmune encephalomyelitis by antibodies against alpha4beta1 integrin. Nature. 1992; 356 63-66

Prof. Dr. Ralf Gold

Institut für MS Forschung, Bereich Humanmedizin und Gemeinnützige Hertie Stiftung, Universität Göttingen

Waldweg 33

37073 Göttingen

Phone: +49/551/3913332

Fax: +49/551/3913348

Email: r.gold@med.uni-goettingen.de